药物诱导/外源亚硝基发生的想法是由人体长期暴露于药物摄入中亚硝胺的影响的可能性驱动的-物质或污染物已被证明是致癌或诱变的。直到最近,科学文献中完全缺乏关于癌症之间关系的数据,多药和多亚硝胺污染。在过去的十年里,黑色素瘤在医学文献中被反复描述为摄入亚硝胺污染的药物的可能副作用,例如:缬沙坦,氢氯噻嗪,氨氯地平,奈比洛尔,比索洛尔和培多普利。然而,当前提供的新数据(5名新患者)的贡献也是由于建立了几种全新药物的可能的致病作用(相对于黑色素瘤),以前不为科学界所知(可能/实际上被致癌物/亚硝胺污染),如:雷尼替丁,瑞舒伐他汀,乐卡地平,利美尼定,Trandolapril,莫索尼定和维拉帕米。异质药物类别(多药)与黑色素瘤的发展和进展的共享新旧药物组合中的主要和联系仍然是相同的:根据FDA的官方清单,在外源亚硝基生成框架中亚硝基成分的可能可用性2023年。摄入黑素瘤后被亚硝胺污染的药物数量正在增加。亚硝基生成仍然是一个新的开始,对黑色素瘤癌变的新认识和新解释,但也可能是癌症。它的进一步阐明看起来不仅仅是有希望的,而且还没有到来。目前更令人担忧的是,科学界必须澄清是否:1)在单一化框架内的亚硝胺或NDSRIs的峰值浓度或2)多重药物内的正常浓度(在FDA/2023的列表中被列为可能被假设的致癌物污染),可以隐藏相对短期的真正的肿瘤发展的风险:皮肤黑素瘤和/或其前体病变。亚硝基发生概念的验证及其与致癌作用的关系,在实践中是根据以下事实实现的:它是相同的单形临床模式(黑色素瘤/发育不良痣)的发生,在摄入具有不同作用机制的药物后发展,被亚硝胺/NDSRIs污染。某些药物的摄入与某些肿瘤的发展之间的统一联系仍然是亚硝胺的存在。药物制剂中存在的成分,被确定为可用性和致癌效力,但尚未反映在包装或处方中。问题仍然存在:为什么?
The idea of drug-induced/exogenic Nitrosogenesis is driven by the possibility of prolonged exposure of the human body to the influence of
nitrosamines within the drug intake - substances or contaminants that have been proven to be carcinogenic or mutagenic one.Until recently, there was a complete lack of data in the scientific literature on the relationship between cancer, polymedication and polycontamination with
nitrosamines. In the last decade, melanoma has been described repeatedly in the medical literature as a possible side-effect within the intake of possibly with nitrosamines contaminated medications such as: Valsartan, Hydrochlorothiazide, Amlodipine, Nebivolol, Bisoprolol and Perindopril. However, the contribution of the currently presented new data (5 new patients) is also due to the establishment of the possible pathogenetic role (with respect to melanoma) of several completely new drugs, previously unknown to the scientific community (potentially/actually contaminated with carcinogens/
nitrosamines), such as: Ranitidine, Rosuvastatin, Lercanidipine, Rilmenidine, Trandolapril, Moxonidine and Verapamil.The leading and connecting link in shared new and old drug combinations of heterogeneous drug classes (polymedication) and melanoma development and progression remains again one and the same: the possible availability of nitroso component in the frame of exogenous nitrosogenesis according to the official FDA lists of 2023.The number of drugs shared as contaminated with nitrosamines after whose intake melanomas occur is increasing. Nitrosogenesis remains a new beginning, a new understanding and new interpretation of the carcinogenesis concerning melanoma, but probably also of cancer in general. Its further elucidation looks more than promising and is yet to come. More than worrying at the moment remains the fact that the scientific community has to clarify if: 1) peak concentrations of
nitrosamines or NDSRIs within the framework of monomedication or 2) normal concentrations within the polymedication (catalogued in the list of FDA/ 2023 as potentially contaminated with hypothetical carcinogens), could hide relatively short-term risk of the development of real tumors: cutaneous melanomas and/or their precursor lesions. The validation of the concept of Nitrosogenesis and its relationship to Сarcinogenesis, is achieved in practice on the basis of the following facts: that it is the occurrence of the same monomorphic clinical pattern (melanoma/dysplastic nevi), developing after the intake of drugs with different mechanism of action, contaminated with nitrosamines/NDSRIs. The unifying link between the intake of certain drugs and the development of certain tumours remains the presence of
nitrosamines. Ingredients that are present in drug preparations, identified as availability and as carcinogenic potency, but not yet reflected in packaging or prescriptions. The question remains: why?